Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report.
Acute humoral rejection (AHR) is generally less responsive to conventional anti-rejection treatment with consequent allograft losses. Therapeutic options include antilymphocyte antibody (ATG), intravenous immunglobulin (IVIG), plasmapheresis, or immunoadsorption with protein A together with intensification of immunsuppression with a tacrolimus/mycophenolate mofetil combination. This report describes a transplant recipient who responded to rituximab therapy as treatment for steroid-, ATG-, IVIG-, and plasmapheresis-resistant AHR.
Celik
A
A
Department of Nephrology, Dokuz Eylul University, School of Medicine, Balcova, Izmir, Turkey.
Saglam
F
F
Cavdar
C
C
Sifil
A
A
Atila
K
K
Sarioglu
S
S
Bora
S
S
Gulay
H
H
Camsari
T
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D015935:Complement C4b / Q000032:analysis; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery*; D016030:Kidney Transplantation / Q000473:pathology*; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis; D011085:Polycystic Ovary Syndrome / Q000150:complications; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D010446:Peptide Fragments; D000069283:Rituximab; D015935:Complement C4b; C032261:complement C4d